^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Colon Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/25/2022
    Excerpt:
    Colon Cancer...systemic therapy...([Nivolumab +/- ipilimumab] or pembrolizumab [preferred]) (dMMR/MSH-I only)
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab

    Excerpt:
    ...dMMR DNA (protein expression by ICH and/or MSI by PCR):...
    Trial ID:
    NIPICOL
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    RECIST 1.1 and iRECIST evaluation for patients with deficient MMR and/or MSI Metastatic Colorectal Cancer treated with nivolumab and ipilimumab.

    Excerpt:
    ...GERCOR will check every patient’s file to confirm the dMMR/ MSI-H patient’s status before inclusion (an anonymized fax or scan document in electronic case report form [e-CRF]). ...
    Trial ID:
    2017-002442-72
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2022
    Title:

    LBA7 - Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study

    Published date:
    09/05/2022
    Excerpt:
    With a median time from first dose to surgery of 5 weeks, pathologic response was observed in 106/107 (99%) pts, consisting of 102/107 (95%) MPR and 4 (4%) PR. PCR was observed in 72/107 (67%) pts. At a median follow-up of 13 months (range 1-57), none of the pts had disease recurrence....In NICHE-2 we confirm the previously reported pathologic responses to short-term neoadjuvant nivolumab plus ipilimumab in a large cohort of dMMR CC pts, with an MPR rate of 95%, including 67% pCR.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Oncol Lett
    Title:

    A pathological complete response after nivolumab plus ipilimumab therapy for DNA mismatch repair-deficient/microsatellite instability-high metastatic colon cancer: A case report

    Published date:
    05/17/2022
    Excerpt:
    The present study reports the case of a large, locally advanced right-sided metastatic deficient mismatch repair/microsatellite instability-high colon cancer, which showed a pathological complete response after combination treatment with nivolumab and ipilimumab.
    DOI:
    10.3892/ol.2022.13332